Bristol-Myers Squibb and Ono Pharmaceutical enter settlement and license agreement
Bristol-Myers and Ono Pharma announced the companies have signed a global patent license agreement with Merck to settle all patent-infringement litigation related to Merck’s PD-1 antibody Keytruda (pembrolizumab). The agreement will result in the dismissal with prejudice of all patent litigation. January 20, 2017